.

The shares of the manufacturer of pharmaceutical products gained up to 4% after the company’s net profit and revenue increased by 91 percent and 14 percent YoY, respectively in the third quarter and announced a second interim dividend of Rs 1.50. 

With a market capitalization of Rs 58,974.72 crore, the shares of Aurobindo Pharma Ltd were trading at Rs 1,006.50 per share, increasing around 0.45 percent as compared to the previous closing price of Rs 1,002.00 a piece. 

Looking into the company’s Performance, Aurobindo Pharma Ltd’s revenue increased by 2 percent on a quarter-on-quarter basis from Rs. 7,219 crores in Q2FY24 to Rs. 7,352 crores in Q3 FY24. Further, revenue increased by 14 percent year on year from Rs. 6,407 crores in Q3FY23 to Rs.7,352 crores in Q3FY24. 

Aurobindo Pharma Ltd’s net profit increased by 25 percent on a quarter-on-quarter basis from Rs.752 crores in Q2FY24 to Rs. 940 crores in Q3FY24. Further, net profit increased by 91 percent yearly from Rs. 491 crores in Q3FY23 to Rs.940 crores in Q3FY24. 

According to the company filing, Aurobindo Pharma Ltd’s Board of Directors has approved the second interim dividend of 150 percent i.e. Rs 1.50 per equity share of the company. 

The company’s US sales in Q3FY24 climbed by 27.1% YoY and 10.2% QoQ to USD 451 Mn, accounting for 51.1% of consolidated revenue, while Specialty & Injectables revenue in the US was USD 112 Mn in Q3FY24, accounting for 25% of total US revenue. The pro forma revenue for Global Specialty & Injectables was USD 150 million. 

During the quarter, the business introduced 21 medicines, four of which were specialty injectables, and gained clearance for 16 ANDAs, seven of which were specialty and injectable. 

Aurobindo Pharma Limited manufactures and markets active pharmaceutical ingredients, branded medications, generic pharmaceuticals, and associated services. Its product portfolio spans seven therapeutic/product categories, including central nervous systems (CNS) and antiretrovirals (ARVs). 

Written by:- Abhishek Singh

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.